Product Description
CLK1 (CDC-like kinase 1), also known as CLK1, is a member of the dual-specificity kinase family that plays a pivotal role in alternative splicing regulation, RNA processing, and gene expression. CLK1 phosphorylates serine/arginine-rich (SR) proteins, a family of splicing factors, thereby modulating their subcellular localization and activity to control splice site selection and mRNA maturation. Beyond its essential physiological functions in pre-mRNA splicing, dysregulation of CLK1 signaling—including overexpression, aberrant kinase activity, and altered splicing patterns—is closely associated with various human cancers (such as breast cancer, colorectal cancer, and leukemia), neurodegenerative diseases (including Alzheimer's disease and frontotemporal dementia), and viral infections, making it a highly validated target for cancer therapy and drug discovery.
Screeningbio’s CLK1 Kinase Assay Kit provides a robust, sensitive, and high-throughput platform for quantifying CLK1 kinase activity and evaluating the potency of tyrosine kinase inhibitors (TKIs).
This kit utilizes the ADP-Glo Kinase Assay platform, a luminescent technology that measures the amount of ADP produced during the kinase reaction.
The assay is performed in two distinct steps:
Kinase Reaction: CLK1 catalyzes the transfer of a phosphate group from ATP to a specific substrate, resulting in the production of phosphorylated substrate and ADP.
ADP-Glo™ Reagent Addition: After the kinase reaction, the ADP-Glo™ Reagent is added to terminate the reaction and deplete any remaining unreacted ATP.
Kinase Detection: The Kinase Detection Reagent is added to simultaneously convert the produced ADP back into ATP, which is then used by luciferase to generate a luminescent signal.
The light intensity produced is directly proportional to the ADP concentration and, consequently, to the enzymatic activity of the CLK1 kinase.
Data